Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules
Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based…
Congratulations to Dr. Vincent Raikhel, assistant professor (General Internal Medicine) who is the recipient of…
karnottJune 26, 2025
Dr. Rainer Storb, professor (Hematology and Oncology) has received the Wallace H. Coulter Award for…
karnottJune 26, 2025
Two species of worms have retained remarkably similar patterns in the way they switch their…
karnottJune 25, 2025
Ever since artificial intelligence (AI) drug developer Xaira Therapeutics launched in April 2024 with a…
karnottJune 25, 2025
CIS43LS is a long-acting monoclonal antibody specific for the Plasmodium falciparum circumsporozoite protein expressed on…
karnottJune 24, 2025
Washington Research Foundation (WRF) has awarded a $275,000 technology commercialization grant to Dr. David Koelle,…
karnottJune 24, 2025
Anthropogenic perturbations to the nitrogen cycle, primarily through use of synthetic fertilizers, is driving an…
karnottJune 23, 2025
Fred Hutch Cancer Center aims to enroll 200,000 patients over the next 10 years in…
karnottJune 23, 2025
